The US Food and Drug Administration (FDA) announced on Monday that the manufacturer of Oseltamivir Phosphate (Tamiflu) Oral Suspension, Genentech, Inc., is experiencing temporary delays in manufacturing of Oral suspension, according to an updated FDA drug shortage listing Jan. 6.
According to the announcement, a brief shortage of Oral Suspension is expected in early–‐mid January. The company expects to have additional supply of Tamiflu for Oral Suspension mid-January 2014.
Company officials say the shortage is due to increased demand of the drug.
In late February, some areas of the southern United States (Little Rock and Atlanta) were reporting “spot” shortages of the “adult” Tamiflu at some pharmacies, according to a posting in Avian Flu Diary.
The FDA notice says “Tamiflu 30 mg, 45 mg and 75 mg capsules remain available. Pediatric patients over 1 year of age can be dosed correctly using the 30 mg and 45 mg capsules.”
Tamiflu is a prescription medicine used to treat the flu (influenza) in people 2 weeks of age and older who have had flu symptoms for no more than 2 days. Tamiflu can also reduce the chance of getting the flu in people 1 year and older.